Table 1.

FDA-approved immune checkpoint inhibitors in cancer treatment.

Target	Antibody	Trade name	Company	Indication (approval date)
CTLA-4	Ipilimumab	YERVOY	Bristol-Myers Squibb (BMS)	Unresectable or metastatic melanoma (2011)
PD-1	Pembrolizumab	KEYTRUDA	Merck Sharp & Dohme (MSD)	Unresectable or metastatic melanoma (approved for patients with disease progression after ipilimumab and, if BRAF V600 mutation positive in 2014, and expanded to initial treatment in 2015)
				Metastatic NSCLC whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy (2015)
	Nivolumab	OPDIVO	Bristol-Myers Squibb (BMS)	Metastatic melanoma (2014, approved for BRAF V600 wild-type tumor in 2015)
				Squamous NSCLC with progression or after platinum-based drugs (2015, and expanded to non-squamous NSCLC later in 2015)
				Advanced metastatic renal cell carcinoma after angiogenic therapy (2015)
				Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin (2016)
				Locally advanced or metastatic urothelial carcinoma which have progression during or following platinum-containing chemotherapy or have progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy (2017)
PD-L1	Atezolizumab	TECENTRIQ	Roche and Genentech	Locally advanced or metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy (2016), but the confirmatory trial failed
				Metastatic NSCLC whose disease progressed during or following platinum-containing chemotherapy (2016)
	Avelumab	BAVENCIO	Merck and Pfizer	Metastatic Merkel-cell carcinoma (2017)